Home › Funds › RTW INVESTMENTS, LP › RARE
RTW INVESTMENTS, LP position in RARE
ULTRAGENYX PHARMACEUTICAL IN · Health Care
RTW INVESTMENTS, LP reported holding 8,529,394 shares of RARE (ULTRAGENYX PHARMACEUTICAL IN) in its Q3 2026 13F filing — a position valued at US$128.2M, representing 1.29% of its reported portfolio and ranking #29 among its reported holdings. RTW INVESTMENTS, LP has disclosed RARE holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How RTW INVESTMENTS, LP's RARE position evolved
RTW INVESTMENTS, LP first disclosed a stake in RARE in Q3 2023 at 5,405,089 shares (US$192.7M). The position peaked in Q1 2024 at 7,087,115 shares, worth US$330.9M. Across 13 filings, RTW INVESTMENTS, LP increased the stake 6 time(s), trimmed it 4 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 8,529,394 shares valued at US$128.2M — an increase of 732,499 shares quarter over quarter.. Notable position changes include a 54% trim in Q2 2024 (shares rose 35% over the following quarter), a 91% increase in Q3 2025 (shares fell 24% over the following quarter), a 114% increase in Q2 2026 (shares fell 55% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 5.41M | $192.69M | New |
| Q4 2023 | 6.89M | $329.34M | Add |
| Q1 2024 | 7.09M | $330.90M | Add |
| Q2 2024 | 3.26M | $133.98M | Reduce |
| Q3 2024 | 1.97M | $109.32M | Reduce |
| Q4 2024 | 1.97M | $82.79M | Hold |
| Q1 2025 | 1.71M | $61.83M | Reduce |
| Q2 2025 | 1.71M | $62.08M | Hold |
| Q3 2025 | 3.26M | $98.01M | Add |
| Q4 2025 | 3.00M | $69.00M | Reduce |
| Q1 2026 | 3.65M | $76.44M | Add |
| Q2 2026 | 7.80M | $260.34M | Add |
| Q3 2026 | 8.53M | $128.20M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RARE and 13F data
RARE (ULTRAGENYX PHARMACEUTICAL IN) is a Health Care company. 20 other funds we track also report a position in RARE — the largest reported positions include FRONTIER CAPITAL MANAGEMENT CO LLC (US$95.1M), Bellevue Group AG (US$66.2M), MPM BioImpact LLC (US$47.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RARE
- FRONTIER CAPITAL MANAGEMENT CO LLC 2.85M sh · $95.09M · Q2 2026
- Bellevue Group AG 1.98M sh · $66.20M · Q2 2026
- MPM BioImpact LLC 1.42M sh · $47.35M · Q2 2026
- Nantahala Capital Management, LLC 2.34M sh · $35.16M · Q3 2026
More on RTW INVESTMENTS, LP
FAQ
How long has RTW INVESTMENTS, LP held RARE?
RTW INVESTMENTS, LP has disclosed RARE holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is RTW INVESTMENTS, LP's current position in RARE?
As of Q3 2026, RTW INVESTMENTS, LP holds 8.53M shares of RARE (ULTRAGENYX PHARMACEUTICAL IN), valued at $128.20M, representing 1.29% of its reported portfolio and ranking #29.
Has RTW INVESTMENTS, LP been buying or selling RARE?
In the latest 13F filing (Q3 2026), RTW INVESTMENTS, LP increased its position in RARE. The position peaked in Q1 2024 at 7.09M shares.
Which other funds hold RARE?
Other major institutional holders of RARE include FRONTIER CAPITAL MANAGEMENT CO LLC, Bellevue Group AG, MPM BioImpact LLC, among 20 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.